RESUMEN
Development of pharmacological tools for the ionotropic glutamate receptors (iGluRs) is imperative for the study and understanding of the role and function of these receptors in the central nervous system. We report the synthesis of 18 analogues of (2 S,3 R)-2-carboxy-3-pyrrolidine acetic acid (3a), which explores the effect of introducing a substituent on the ε-carbon (3c-q). A new synthetic method was developed for the efficient synthesis of racemic 3a and applied to give expedited access to 13 racemic analogues of 3a. Pharmacological characterization was carried out at native iGluRs, cloned homomeric kainate receptors (GluK1-3), NMDA receptors (GluN1/GluN2A-D), and excitatory amino acid transporters (EAAT1-3). From the structure-activity relationship studies, several new ligands emerged, exemplified by triazole 3p-d1, GluK3-preferring (GluK1/GluK3 Ki ratio of 15), and the structurally closely related tetrazole 3q-s3-4 that displayed 4.4-100-fold preference as an antagonist for the GluN1/GluN2A receptor ( Ki = 0.61 µM) over GluN1/GluN2B-D ( Ki = 2.7-62 µM).
Asunto(s)
Proteínas de Transporte de Glutamato en la Membrana Plasmática/metabolismo , Prolina/análogos & derivados , Prolina/farmacología , Receptores Ionotrópicos de Glutamato/metabolismo , Animales , Diseño de Fármacos , Humanos , Ligandos , Modelos Moleculares , Prolina/síntesis química , Ratas , Relación Estructura-ActividadRESUMEN
Reaction conditions allowing a stereoretentive cross-coupling of alkenyl sulfides with Grignard reagents using ligand-free Pd catalysis are discussed here. The presence of an adequately positioned OH function is a key feature that allows a Mg-promoted Lewis acid activation of the mercaptide leaving group. This easy to implement procedure actually relies on an in situ generation of stable Pd nanoparticles by simply mixing Pd2(dba)3, the Grignard reagent, and the vinyl sulfide cross-coupling partner in THF. The efficiency of this procedure has been demonstrated in a natural product total synthesis context.
RESUMEN
Our study of the synthesis of the aglycone of tiacumicin B is discussed here. We imagined two possible strategies featuring a main retrosynthetic disconnection between C13 and C14. The first strategy was based on Suzuki-Miyaura cross-coupling of 1,1-dichloro-1-alkenes, but the failure of this pathway led us to use a Pd/Cu-dual-catalyzed cross-coupling of alkynes with allenes that had never been implemented before in a total synthesis context. We used density functional theory calculations to guide our strategic choices concerning a [2.3]-Wittig rearrangement step and the final ring-size selective Yamaguchi macrolactonization. This led to two syntheses of the aglycone of tiacumicin B, with one of last generation delivering ultimately an adequately protected and glycosylation-ready aglycone.
RESUMEN
Tiacumicin B is an antibiotic endowed with the remarkable ability to interact with a new biological target, giving it an inestimable potential in the context of the ever-growing and worrisome appearance of resistances of bacteria and mycobacteria to antibiotics. The synthesis of an aglycone of tiacumicin B ready for glycosylation is reported. The key steps of this approach are a [2,3]-Wittig rearrangement, a Pd/Cu-catalyzed allene-alkyne cross-coupling, a E-selective cross-metathesis, and a final ring-size selective macrolactonization.